Implantable Cardiac Device Patent Landscape 2026
Implantable Cardiac Device Patent Landscape in 2026
The implantable cardiac device patent field is heavily concentrated, with the top five filers commanding 74% of the hundred largest filers’ combined records and Medtronic holding a commanding lead. The field peaked around 2017 and annual filing volume has since eased, placing the technology in a mature-to-declining stage where incremental differentiation and adjacent technical branches represent the primary remaining entry levers.
Medtronic leads a tightly consolidated field with a wide gap to challengers
Medtronic ranks first with 7,382 patent records, nearly 1.8× the second-ranked Cardiac Pacemakers Inc (4,138 patent records), establishing an unusually steep leader advantage even within a concentrated field.
The top five filers — Medtronic, Cardiac Pacemakers, Pacesetter, Biotronik, and Greatbatch — together account for 74% of the hundred largest filers’ combined patent records, indicating a first-tier club with a structural barrier that is difficult for new entrants to close through conventional broad-spectrum filing.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Medtronic Inc | 7,382 | |
| 2 | Cardiac Pacemakers Inc | 4,138 | |
| 3 | Pacesetter Inc | 2,191 | |
| 4 | BIOTRONIK SE & CO KG | 1,487 | |
| 5 | Greatbatch Ltd | 718 | |
| 6 | St. Jude Medical AB | 472 | |
| 7 | ElectroCore Inc | 390 | |
| 8 | Intermedics Inc | 257 | |
| 9 | ELA Medical SA | 205 | |
| 10 | BackBeat Medical Inc | 203 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Cameron Health Inc | 201 | |
| 12 | Atacor Medical Inc | 155 | |
| 13 | Beta Bionics Inc | 135 | |
| 14 | Biotronix CRM Patent AG | 126 | |
| 15 | Impulse Dynamics NV | 117 | |
| 16 | Siemens AG | 114 | |
| 17 | EBR Systems Inc | 111 | |
| 18 | Advanced Neuromodulation Systems Inc | 104 | |
| 19 | MicroPort Sorin CRM (Shanghai) Co Ltd | 90 | |
| 20 | Telectronics | 87 |
Medtronic’s and Cardiac Pacemakers’ scale implies deep prior-art coverage across core electrotherapy and sensing subclasses, meaning later entrants need focused niche or adjacent-branch strategies to find protectable space without triggering dense prior-art thickets.
Filing counts for 2024–2026 are subject to publication lag and understate true recent activity; the trend read should be anchored on 2017–2022 data. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Annual volume has eased from a 2017 peak; electrotherapy dominates the technology mix
The filing trend chart captures the arc from peak activity through the current eased phase, while the technology composition chart reveals how unevenly coverage is distributed across IPC branches.
Annual filing trend
Annual filings reached a high point in 2017 and have moderated in each subsequent period; 2024 and 2025 counts are understated due to publication lag and should not be read as a steeper decline than the 2017–2022 trend already indicates.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61N (electrotherapy and radiation therapy) dominates the IPC mix by a wide margin, followed at a distance by A61B (diagnosis and surgery) and A61M (devices for body fluids); branches such as G16H (healthcare informatics), A61F (implants and prostheses), and G06F (digital data processing) each represent low single-digit shares, signalling relatively sparse coverage relative to their technical relevance to next-generation connected and drug-eluting devices.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Implantable cardiac device
An implantable cardiac device, such as a cardiac pacemaker including a power source, a pulse generator, and a housing having a curved top surface and an opposed bottom surface for enclosing the power source and the pulse generator. The housing is operable to receive at least one lead that is configured to connect the housing to a patient’s heart, when in… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Medical procedures and apparatus using intrabody p… | 3,247 |
| 2 | Subcutaneous multi-electrode sensing system, metho… | 1,874 |
| 3 | Coated implantable medical device | 1,736 |
| 4 | Coated implantable medical device | 1,683 |
| 5 | Combined remodeling control therapy and anti-remod… | 1,667 |
| 6 | Implantable sensor and system for measurement and … | 1,577 |
| 7 | Implantable ambulatory electrocardiogram monitor | 1,557 |
| 8 | Implantable microstimulator | 1,541 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D investment decisions
Four structural signals — maturity stage, concentration, collaborative activity, and geographic distribution — collectively shape where new investment is most likely to find protectable, commercially relevant space.
Post-peak field with incremental innovation momentum
The lifecycle evidence classifies this field as declining, with annual filings easing back from the 2017 peak. Core electrotherapy and pacing architectures are well-covered, meaning primary innovation pressure has shifted toward miniaturisation, sensor integration, and connectivity sub-themes. R&D programs targeting only the core A61N1 subclass face dense prior-art and limited differentiation room.
Lifecycle: Decline74% of top-100 filer records held by five players
The top five filers hold 74% of the hundred largest filers’ combined patent records, with Medtronic alone contributing 7,382 patent records. This degree of concentration signals that freedom-to-operate analysis is essential before entering the core subclasses. Niche device categories — such as subcutaneous or leadless architectures — and adjacent branches remain comparatively less encumbered.
High concentrationCardiac Pacemakers and Medtronic anchor the co-filing network
Cardiac Pacemakers Inc is the most active co-filer, collaborating with Duke University (10 joint filings), the Columbia University trustees (4), and the Research Foundation of the State University of New York (4). Medtronic co-filed with the U.S. Department of Veterans Affairs (6 filings) and Maastricht University Medical Center (3). Biotronik co-filed with the Max Planck Society (3). These pairings indicate that academic partnerships are a primary mechanism through which established players extend their technical reach.
Industry-academia linksU.S.-centric protection with limited Asia-Pacific depth
The United States leads jurisdiction coverage by a wide margin, followed by Europe (EPO) and WIPO (PCT). Australia and Canada constitute a secondary tier. Japan and China each show very limited patent-record counts, which is notable given both markets’ growing importance for implantable device commercialisation. Entrants seeking to establish exclusive positions in Asia-Pacific may face fewer filing barriers in those jurisdictions.
U.S.-dominantGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Cardiac Pacemakers Inc | Duke University | 10 |
| Medtronic Inc | U.S. Department of Veterans Affairs | 6 |
| Cardiac Pacemakers Inc | Critical Care Diagnostics Inc | 4 |
| Cardiac Pacemakers Inc | The Trustees of Columbia University in the City of New York | 4 |
| Cardiac Pacemakers Inc | The Research Foundation of State University of New York | 4 |
| Medtronic Inc | Maastricht University Medical Center | 3 |
| Cardiac Pacemakers Inc | North Dakota State University Research Foundation | 3 |
| Biotronik SE & Co KG | Max Planck Society for the Advancement of Science | 3 |
| Greatbatch Ltd | Galvani Bioelectronics Ltd | 3 |
| Medtronic Inc | Maastricht University | 2 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Medtronic and Cardiac Pacemakers lead on volume; Biotronik and Greatbatch differentiate by subclass emphasis
The top six filers by patent records all show declining recent momentum, consistent with the field-wide post-peak trend, but their technology emphases and scale advantages differ materially.
Medtronic
Medtronic holds 7,382 patent records and focuses primarily on A61N1 (electrotherapy, 4,662 records), A61B5 (diagnosis and surgery, 1,778 records), and A61M5 (devices for body fluids, 193 records), indicating broad coverage across pacing, sensing, and drug-delivery adjacent functions. Recent momentum is down 37% versus the prior period, consistent with a maturing core portfolio rather than an exit from the space.
families: 7,382Cardiac Pacemakers Inc
Cardiac Pacemakers Inc holds 4,138 patent records with concentration in A61N1 (2,714 records) and A61B5 (1,029 records), mirroring Medtronic’s subclass profile at roughly 60% of the scale. Recent filing trend is down 64%, the steepest decline among the top six, suggesting active portfolio rationalisation or consolidation of filing strategy. Its extensive academic co-filing relationships — notably with Duke University — indicate continued engagement through collaborative rather than purely proprietary channels.
families: 4,138| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Medtronic Inc | 271 | ▼ -37% |
| Cardiac Pacemakers Inc | 44 | ▼ -64% |
| Pacesetter Inc | 242 | ▼ -11% |
| Biotronik SE & Co KG | 145 | ▼ -33% |
| Greatbatch Ltd | 34 | ▼ -45% |
| ElectroCore Inc | 47 | ▼ -34% |
Under-served IPC branches adjacent to the dominant electrotherapy core
Several IPC branches appear at low share relative to their plausible technical relevance to next-generation implantable cardiac devices; these represent observations of relative sparsity rather than validated commercial opportunities, and each would require freedom-to-operate and market validation work before committing R&D resources.
G16H · Healthcare Informatics
G16H accounts for only 2% of patent records in this corpus despite the rapid proliferation of remote cardiac monitoring, AI-assisted arrhythmia detection, and cloud-connected device management platforms. The sparse coverage relative to clinical demand suggests that software-layer intellectual property — covering data pipelines from implanted sensors to clinical decision systems — may be comparatively open. Realistic entry paths include filing at the intersection of G16H and A61N1 subclasses, targeting device-to-cloud data architectures rather than the device hardware itself.
Search this in Eureka →A61F · Implants & Prostheses
A61F holds only 2% of patent records in this corpus, yet structural implant design — including leadless pacemaker housings, biocompatible enclosures, and hybrid cardiac support scaffolds — sits at the intersection of A61F and A61N1. The low relative density suggests that mechanical and materials innovation in implant architecture is less contested than electrical function claims. Entry paths include novel biocompatible material systems, miniaturised hermetic packaging, or hybrid mechano-electrical implant designs that cross both subclasses.
Search this in Eureka →How leading filers differ across technology subclasses
Strength of each leader across the main technology routes.
| Player | A61N 1 · Electrotherapy & radiation therapy | A61B 5 · Diagnosis & surgery | A61M 25 · Devices for body fluids | A61B 17 · Diagnosis & surgery | A61M 5 · Devices for body fluids |
|---|---|---|---|---|---|
| Medtronic Inc | Strong · 4,662 | Moderate · 1,778 | Emerging · 172 | Emerging · 141 | Emerging · 193 |
| Cardiac Pacemakers Inc | Strong · 2,714 | Moderate · 1,029 | Emerging · 48 | Emerging · 45 | Emerging · 46 |
| Pacesetter Inc | Strong · 1,419 | Moderate · 443 | Emerging · 122 | Emerging · 92 | Emerging · 6 |
| Biotronik SE & Co KG | Strong · 827 | Moderate · 220 | Emerging · 34 | Emerging · 23 | Emerging · 7 |
| Greatbatch Ltd | Strong · 518 | Absent | Absent | Absent | Absent |
| ElectroCore Inc | Strong · 304 | Emerging · 42 | Absent | Absent | Absent |
| St. Jude Medical AB | Strong · 261 | Moderate · 70 | Absent | Absent | Absent |
Frequently asked questions
The landscape covers 4,981 patent families. This total is independent of the patent-record counts used in the applicant ranking, where a single family may be counted under multiple records.
Medtronic leads with 7,382 patent records, nearly 1.8 times the second-ranked Cardiac Pacemakers Inc at 4,138 patent records.
The evidence classifies the field as declining: annual filings peaked in 2017 and have eased in each subsequent year. The most recent two years of data are affected by publication lag, so the magnitude of the recent dip should be interpreted cautiously.
The United States leads by a wide margin, followed by Europe (EPO) and WIPO (PCT). Australia and Canada form a secondary tier. Japan and China each show comparatively low patent-record counts, which may represent reduced prior-art density in those markets.
Cardiac Pacemakers Inc is the most active co-filer, with 10 joint filings alongside Duke University and additional collaborations with Columbia University, the Research Foundation of the State University of New York, and Critical Care Diagnostics. Medtronic co-filed with the U.S. Department of Veterans Affairs and Maastricht University Medical Center. These pairings indicate that industry-academia partnerships are a primary channel for extending portfolios in this space.
G16H (healthcare informatics), A61F (implants and prostheses), and A61K (medicinal preparations) each account for 2% or less of patent records in this corpus. These branches cover remote monitoring software, structural implant design, and drug-eluting device chemistries respectively — areas where coverage is sparse relative to their technical relevance to next-generation implantable cardiac devices.
Ready to map your own implantable cardiac device landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.